Release details

2017-08-09 15:15 CEST
  • Print
  • Share Share
en

Shire plc : Director/PDMR Shareholding

Director/PDMR Shareholding
 
August 9, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG)
 
Notification of transaction by person discharging managerial responsibilities and person closely associated with them
 
1. Details of the person discharging managerial responsibilities ("PDMR") / person closely associated them ("PCA")
a) Name Kim Stratton / Peter Stratton
2. Reason for the notification
a) Position / status Head of International Commercial (PDMR) / PCA of Kim Stratton
b) Initial notification / amendment Initial notification
3. Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a) Name Shire plc
b) LEI 54930005LQRLI2UXRQ59
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Shire plc Ordinary Shares of 5 pence each ("Ordinary Shares")

 

 
Identification code ISIN: JE00B2QKY057
b) Nature of the transaction Transfer of Ordinary Shares held by Kim Stratton to a joint account held by Kim Stratton and Peter Stratton and the pledge of such Ordinary Shares as security for a loan.
c) Price(s) and volume(s) Price(s) Volume(s)
N/A 5,943
d) Aggregated information

- Aggregated volume

- Price
N/A (single transaction)
e) Date of the transaction August 8, 2017
f) Place of the transaction Outside a trading venue

Oliver Strawbridge
Senior Assistant Company Secretary

For further information please contact:

Investor Relations    
Ian Karp ikarp@shire.com +1 781 482 9018
Robert Coates rcoates@shire.com +44 1256 894874
Media    
Lisa Adler lisa.adler@shire.com +1 617 588 8607
Debbi Ford debbi.ford@shire.com  +1 617 949 9083

NOTES TO EDITORS

About Shire

Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

www.shire.com

HUG#2126432